KR870006087A - 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법 - Google Patents

오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법 Download PDF

Info

Publication number
KR870006087A
KR870006087A KR860011020A KR860011020A KR870006087A KR 870006087 A KR870006087 A KR 870006087A KR 860011020 A KR860011020 A KR 860011020A KR 860011020 A KR860011020 A KR 860011020A KR 870006087 A KR870006087 A KR 870006087A
Authority
KR
South Korea
Prior art keywords
gpir
improved
producing
protecting group
binding
Prior art date
Application number
KR860011020A
Other languages
English (en)
Other versions
KR950007216B1 (ko
Inventor
까셀라 피에르
부리 베르나르
까나 크자비에
Original Assignee
미셀드아스
소시에떼아노님사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8518982A external-priority patent/FR2591895B1/fr
Priority claimed from FR8611644A external-priority patent/FR2602683B1/fr
Application filed by 미셀드아스, 소시에떼아노님사노피 filed Critical 미셀드아스
Publication of KR870006087A publication Critical patent/KR870006087A/ko
Application granted granted Critical
Publication of KR950007216B1 publication Critical patent/KR950007216B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Abstract

내용 없음

Description

오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 정액 주사한 쳔연 리신의 A 사슬 및 변형된 A-1a 사슬에 대한 시간에 따른 혈장이탈곡선을 나타낸다.
제2도는 토끼에 주사한 여러가지 A-1a 사슬의 24시간 후의 RPC(상대 혈장농도)를 종축에 나타내고, 횡측에는 피요오데이트-시아노보로히드리드의 처리시간을 나타내어 처리시간의 중요성을 나타낸 곡선이다.
제3도는 정맥 주사한 통상의 IT AT15E(제 1곡선) 및 IT(A-1a)15E(제 2곡선)의 시간에 따른 혈장이 탈곡선을 나타낸다.

Claims (9)

  1. GPIR를 피요오데이트 수용액 및 시아노보로히드리드 수용액의 연합적 처리단계를 함유함을 특징으로 하는, 천연 GPIR의 리보솜-비활성화 작용 및 GPIR에 대한 생체내 지속작용성을 갖는 개량된 GPIR을 제조하는 방법.
  2. 제1항에 있어서, GPIR의 티올기중 최소한 하나가 처리중에 보호됨을 특징으로 하는 개량된 GPIR의 제조방법.
  3. 제1항에 있어서, pH5~7의 수용액에서 0~15°의 온도로 빛을 차단하고 0.2~24시간 처리함을 특징으로 하는 개량된 GPIR의 제조방법.
  4. 제1항에 있어서, 반응용액이 1~10mg/ml의 반응성 A사슬, 10~50mM 알칼린 퍼요오데이트 및 10~200mM의 소디움 시아노보로히드리드를 함유함을 특징으로 하는 개량된 GPIR의 제조방법.
  5. 제4항에 있어서, GPIR을 미리 통상의 SH 보호기로 처리하고, IO4 -이온 및 시아노보로히드리드로 처리한 후, 상기 SH기를 방출함을 특징으로 하는 개량된 GPIR의 제조방법.
  6. 제5항에 있어서, SH 보호기가 2,2'-디니트로-5,5'-디티오-디벤조산 및 3-(2-피리딜디술파닐)프로 피온산으로 부터 선택되고, SH기의 탈보호기가 2-머켑토에탄올의 작용으로 수행됨을 특징으로하는 개량된 GPIR의 제조방법.
  7. 항체 또는 항체 단편을 제1항부터 제6항의 어느 한항의 방법으로 제조한 개량된 GPIR과 결합하는 것을 포함함을 특징으로 하는, 생체내에서 지속-작용성을 갖는 면역독소의 제조방법.
  8. 제7항에 있어서, 항체 또는 항체단편과 개량된 GPIR 사이의 결합이 디설파이드가교로 이루어짐을 특징으로 하는 면역독소의 제조방법.
  9. 제8항에 있어서, 1-에틸-3-(3-디메틸아미노프로필) 카르보디이미드로 활성화된 N-숙신이미딜-3-(2-피리딜디티오)프로피오네이트 또는 3-(2-피리딜디술파닐) 프로피온산 중에서 선택된 이종 2 작용제에 의해 결합반응이 수행됨을 특징으로 하는 면역독소의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860011020A 1985-12-20 1986-12-20 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법 KR950007216B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR8518982A FR2591895B1 (fr) 1985-12-20 1985-12-20 Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
FR85.18982 1985-12-20
FR8611644 1986-08-12
FR86.11644 1986-08-12
FR8611644A FR2602683B1 (fr) 1986-08-12 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction

Publications (2)

Publication Number Publication Date
KR870006087A true KR870006087A (ko) 1987-07-09
KR950007216B1 KR950007216B1 (ko) 1995-07-04

Family

ID=26224906

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860011020A KR950007216B1 (ko) 1985-12-20 1986-12-20 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법

Country Status (12)

Country Link
US (2) US4911912A (ko)
EP (1) EP0229564B1 (ko)
JP (1) JPH0780903B2 (ko)
KR (1) KR950007216B1 (ko)
AU (1) AU611848B2 (ko)
DE (1) DE3674566D1 (ko)
DK (1) DK611986A (ko)
ES (1) ES2018783B3 (ko)
GR (1) GR3001236T3 (ko)
IE (1) IE59650B1 (ko)
IL (1) IL80973A (ko)
PT (1) PT83947B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
GB2225324B (en) * 1988-11-25 1993-02-03 Branko Kozulic Stabilization of glycoproteins
US5258501A (en) * 1988-11-25 1993-11-02 Slobodan Barbaric Stabilization of glycoproteins
US5112607A (en) * 1991-06-05 1992-05-12 The United States Of America As Represented By The Secretary Of The Army Potentiation of immunotoxin action by Brefeldin A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
CA1083508A (fr) * 1975-11-13 1980-08-12 Jacques Grange Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique
US4154726A (en) * 1978-03-20 1979-05-15 Standard Oil Company (Indiana) Process for modifying the cell wall of single-cell microorganisms using periodate ions
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
EP0272253A4 (en) * 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.

Also Published As

Publication number Publication date
KR950007216B1 (ko) 1995-07-04
EP0229564A1 (fr) 1987-07-22
US5106956A (en) 1992-04-21
PT83947B (pt) 1989-05-12
PT83947A (fr) 1987-01-01
IE863306L (en) 1987-06-20
IL80973A0 (en) 1987-03-31
DE3674566D1 (de) 1990-10-31
DK611986D0 (da) 1986-12-18
IL80973A (en) 1992-08-18
DK611986A (da) 1987-06-21
GR3001236T3 (en) 1992-07-30
AU611848B2 (en) 1991-06-27
JPH0780903B2 (ja) 1995-08-30
AU6662986A (en) 1987-06-25
EP0229564B1 (fr) 1990-09-26
IE59650B1 (en) 1994-03-09
JPS62175500A (ja) 1987-08-01
US4911912A (en) 1990-03-27
ES2018783B3 (es) 1991-05-16

Similar Documents

Publication Publication Date Title
Rahim et al. Identification and immunocytochemical localization of two different carbonic anhydrase isoenzymes in teleostean fish erythrocytes and gill epithelia
Sherbet et al. Characterisation of Escherichia coli cell surface by isoelectric equilibrium analysis
RU94045908A (ru) Композиция, способ обработки неопластической клетки, способ уничтожения неопластической клетки
Smith et al. Protective effect of oxidized glutathione in acute sulfide poisoning
KR870006087A (ko) 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
EP0199103A2 (en) Process for preventing or reversing cataract formation using protein modification reagents
Martinez et al. Nitric oxide (NO) synthase immunoreactivity in the starfish Marthasterias glacialis
CN104758946A (zh) 一种抗体偶联药物及其制备方法和应用
Fowler Proton translocation in chloroplasts and its relationship to electron transport between the photosystems
Foder et al. Decrease of apparent calmodulin affinity of erythrocyte (Ca2++ Mg2+)-ATPase at low Ca2+ concentrations
YAMAMOTO et al. Interaction of alkali light chain 1 with actin: effect of ionic strength on the cross-linking of alkali light chain 1 with actin
DE2742529A1 (de) Plasminogen-aktivatorkomplex, verfahren zu seiner herstellung und ihn enthaltendes arzneimittel
Avigliano et al. Removal of non-blue copper from ascorbate oxidase
Freedman et al. Preparation of red cells coated with C4 and C3 subcomponents and production of anti‐C4d and anti‐C3d
AU587054B2 (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
AU609380B2 (en) Ricin-antibody conjugates
KR870006086A (ko) 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
Jensen et al. Differences in the proteinase inhibition mechanism of human α2‐macroglobulin and pregnancy zone protein
EP0303236A3 (en) Lignosulfonate based pharmacologic agent with anti-thrombotic activity
FR2582515A1 (fr) Procede de preparation de gamma-gobulines administrables par voie intraveineuse et gamma-globulines obtenues
JPH0582400B2 (ko)
WO1998032367A3 (en) Device and method for preparing veins
Kim et al. A study of dithiothreitol inactivation of the enzyme rhodanese
CA1269327A (en) Process for preventing or reversing cataract formation using protein modification reagents
Kistner et al. Disulfide formation in reduced tetanus toxin by thioredoxin: the pharmacological role of interchain covalent and noncovalent bonds

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee